430 related articles for article (PubMed ID: 10087161)
1. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of rosmarinic acid on Lck SH2 domain binding to a synthetic phosphopeptide.
Ahn SC; Oh WK; Kim BY; Kang DO; Kim MS; Heo GY; Ahn JS
Planta Med; 2003 Jul; 69(7):642-6. PubMed ID: 12898421
[TBL] [Abstract][Full Text] [Related]
3. TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues.
Nyakeriga AM; Garg H; Joshi A
Cytometry A; 2012 Sep; 81(9):797-805. PubMed ID: 22674786
[TBL] [Abstract][Full Text] [Related]
4. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
5. Calcium-induced p56(Lck) phosphorylation in human T lymphocytes via calmodulin dependent kinase.
Franklin RA; Mcleod A; Robinson PJ
Biochem Biophys Res Commun; 1999 Jun; 259(2):283-6. PubMed ID: 10362499
[TBL] [Abstract][Full Text] [Related]
6. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
[TBL] [Abstract][Full Text] [Related]
7. Hypophosphorylated TCR/CD3zeta signals through a Grb2-SOS1-Ras pathway in Lck knockdown cells.
Methi T; Ngai J; Vang T; Torgersen KM; Taskén K
Eur J Immunol; 2007 Sep; 37(9):2539-48. PubMed ID: 17683112
[TBL] [Abstract][Full Text] [Related]
8. CD28-dependent killing by human YT cells requires phosphatidylinositol 3-kinase activation.
Lu Y; Rodriguez R; Bjorndahl J; Phillips CA; Trevillyan JM
Eur J Immunol; 1996 Jun; 26(6):1278-84. PubMed ID: 8647205
[TBL] [Abstract][Full Text] [Related]
9. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
Schnaider T; Somogyi J; Csermely P; Szamel M
Cell Stress Chaperones; 2000 Jan; 5(1):52-61. PubMed ID: 10701840
[TBL] [Abstract][Full Text] [Related]
10. Intracellular Phospho-Flow cytometry reveals novel insights into TCR proximal signaling events. A comparison with Western blot.
Haas A; Weckbecker G; Welzenbach K
Cytometry A; 2008 Sep; 73(9):799-807. PubMed ID: 18548611
[TBL] [Abstract][Full Text] [Related]
11. Cloning, characterization, and expression pattern of Atlantic halibut (Hippoglossus hippoglossus L.) CD4-2, Lck, and ZAP-70.
Øvergård AC; Nerland AH; Patel S
Fish Shellfish Immunol; 2010 Dec; 29(6):987-97. PubMed ID: 20728542
[TBL] [Abstract][Full Text] [Related]
12. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Krystal GW; DeBerry CS; Linnekin D; Litz J
Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of lck and loss of TCR-mediated signaling upon persistent engagement with complexes of peptide:MHC molecules.
Lee JE; Cossoy MB; Chau LA; Singh B; Madrenas J
J Immunol; 1997 Jul; 159(1):61-9. PubMed ID: 9200439
[TBL] [Abstract][Full Text] [Related]
14. The cytoplasmic domain of rat NKR-P1 receptor interacts with the N-terminal domain of p56(lck) via cysteine residues.
Campbell KS; Giorda R
Eur J Immunol; 1997 Jan; 27(1):72-7. PubMed ID: 9022000
[TBL] [Abstract][Full Text] [Related]
15. Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner.
Won J; Hur YG; Hur EM; Park SH; Kang MA; Choi Y; Park C; Lee KH; Yun Y
Eur J Immunol; 2003 Apr; 33(4):870-9. PubMed ID: 12672052
[TBL] [Abstract][Full Text] [Related]
16. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
17. Involvement of tyrosine kinase p56/Lck in apoptosis induction by anticancer drugs.
Gruber C; Henkel M; Budach W; Belka C; Jendrossek V
Biochem Pharmacol; 2004 May; 67(10):1859-72. PubMed ID: 15130763
[TBL] [Abstract][Full Text] [Related]
18. The catalytic domain of pp56(lck), but not its regulatory domain, is sufficient for inducing IL-2 production.
Carrera AC; Calvo V; Borlado LR; Paradis H; Alemany S; Roberts TM; Martinez-A C
J Immunol; 1996 Nov; 157(9):3775-82. PubMed ID: 8892605
[TBL] [Abstract][Full Text] [Related]
19. Conversion of p56(lck) to p60(lck) in human peripheral blood T lymphocytes is dependent on co- stimulation through accessory receptors: involvement of phospholipase C, protein kinase C and MAP-kinases in vivo.
Schröder AJ; Quehl P; Müller J; Samstag Y
Eur J Immunol; 2000 Feb; 30(2):635-43. PubMed ID: 10671221
[TBL] [Abstract][Full Text] [Related]
20. MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells.
Mukherjee P; Tinder TL; Basu GD; Gendler SJ
J Leukoc Biol; 2005 Jan; 77(1):90-9. PubMed ID: 15513966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
